Andras Heczey, MD, Baylor College of Medicine, Houston, TX, describes current unanswered questions in the management of pediatric hepatoblastoma. Whilst conventional chemotherapy typically consisting of cisplatin and doxorubicin have been the standard of care, a lack of innovative therapies have failed to reduce the high toxicity and long treatment times associated with chemotherapy. Cellular therapies under development may provide additional benefit to this group of patients. This interview took place at the 2022 San Antonio Liver Cancer Symposium (SALCS) in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.